Gut microbiota on admission as predictive biomarker for acute necrotizing pancreatitis

Menglian Zou,†, Zihan Yang,†, Yue Fan, Liang Gong,‡, Ziyong Han, Li Ji, Xiaomin Hu,* and Dong Wu,*

1Department of Gastroenterology, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China, 2Department of Medical Research Center, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China

Background: Acute necrotizing pancreatitis (NP), a severe form of acute pancreatitis (AP), has higher mortality and worse outcome than non-necrotizing pancreatitis (non-NP). Infected NP is a devastating subgroup of NP. To date neither NP nor infected NP has robust prediction strategies, which may delay early recognition and timely intervention. Recent studies revealed correlations between disturbed gut microbiota and AP severity. Some features of intestinal microbiota have the potential to become biomarkers for NP prediction.

Methods: We performed 16S rRNA sequencing to analyze gut microbiota features in 20 healthy controls (HC), and 58 AP patients on hospital admission. The AP patients were later classified into NP and non-NP groups based on subsequent diagnostic imaging features. Random forest regression model and ROC curve were applied for NP and infected NP prediction. PIRCUSt2 was used for bacterial functional pathway prediction analysis.

Results: We found that the three groups (HC, NP, and non-NP) had distinct microorganism composition. NP patients had reduced microbial diversity, higher abundance of Enterobacteriales, but lower abundance of Clostridiales and Bacteroidales compared with the non-NP group. Correlation analyses displayed that intestine bacterial taxonomic alterations were related to severity, ICU admission, and prognosis. By pathway prediction, species more abundant in NP patients had positive correlation with synthesis and degradation of ketone bodies, and benzoate degradation. Enterococcus faecium (ASV2) performed best in discriminating NP and non-NP patients. Finegoldia magna (ASV3) showed the maximal prediction capacity among all ASVs and had comparable accuracy with Balthazar CT to detect patients with infected NP.

Conclusions: Our study suggests that NP patients have distinct intestinal microbiota on admission compared to non-NP patients. Dysbiosis of intestinal microbiota might influence NP progression through ketone body or benzoate metabolism. Enterococcus faecium and Finegoldia magna are potential predictors for NP and infected NP. Our findings explore biomarkers
which may inform clinical decision-making in AP and shed light on further studies on NP pathophysiology and management.

KEYWORDS
acute pancreatitis, necrotizing pancreatitis, gut microbiota, dysbiosis, prognosis

Introduction

Acute pancreatitis (AP) is a leading cause for acute admission due to gastrointestinal diseases and results in enormous morbidity and mortality (1, 2). The incidence of AP is around 34 per 100,000 cases worldwide, and the overall incidence increases by 3.07% per year, inducing substantial medical and social burden (3, 4).

There are two subtypes of AP: interstitial edematous pancreatitis and necrotizing pancreatitis. Necrotizing pancreatitis (NP), a non-mild AP manifestation, represents (peri-)pancreatic parenchymal necrosis and accounts for 10%-20% of AP patients (5, 6). Developing NP leads to unfavorable prognosis, that is, the mortality is about 15%, and for those with infected NP (INP), even as high as 30%-39% (7). Early recognition of patients who are prone to develop NP is crucial, particularly on clinical admission, because proper triage, close monitoring, early intervention, and multidisciplinary treatment may prevent organ dysfunction and lethal outcome (8). Timely aggressive antibiotic treatment and proper drainage or debridement is indicated in patients with infected NP. Therefore, early prediction of NP with or without infection is of clinical significance.

However, neither etiologic factors (gallstones, alcohol use, etc.) nor demographics features are conclusively risk factors to necrosis formation (9). A series of studies have evaluated the prediction potential of a variety of biomarkers and scoring systems for NP or infected NP, but none are robust enough. Some studies have investigated lab indicators for necrosis prediction, but none have been solid (10, 11). Existing scoring systems, for instance the Ranson score, the acute physiology and chronic health evaluation-II (APACHE-II), the computed tomography severity index (CTSI), or the Bedside Index of Severity in Acute Pancreatitis (BISAP) could not differentiate the aseptic or infected necrosis (12). Thus more efficient and cost-effective methods for prediction of NP and infected NP are needed.

Recent decades have witnessed that gut microbiota alteration were closely related to the progression of AP. Around 60% of patients with AP had varying degrees of intestinal barrier injury, which led to increased intestinal mucosal permeability and intestinal bacterial translocation, furthering the exacerbation of NP, presumably developing MODS in the end (13). Moreover, a previous study indicated that severe AP (SAP) had a lower relative abundance of beneficial bacteria (Bifidobacterium etc.), and a higher relative abundance of potentially pathogenic bacteria (Enterococcus etc.), in comparison with MAP patients (14). These studies inspired the potential role of the microbiota in NP progression. It has been evidenced that (peri-)pancreatic collections are liable to be infected with gut microorganisms (15). Thus, gut microbiome may help with pathogen prediction and antibiotic selection. Therefore, clarifying the role of dysbiosis in NP will not only enrich our knowledge regarding the "gut microbiota-pancreas axis", but also shed light on suitable therapy.

To determine the prediction potential of gut microbiota for NP outcome on admission, we performed a prospective, observational study. We studied the association between intestinal microbiota and the prognosis of patients with NP to unveil potential microbiota biomarkers and lay the foundation for future research translation. We hypothesized that key features of the gut microbiome (diversity, community composition, certain ASVs) would predict exacerbation of NP patients on admission.

Materials and methods

Study population and sample collection

We performed a prospective, observational study in a single center. We enrolled 20 healthy controls and 58 AP patients at Peking Union Medical College Hospital (PUMCH), Beijing, China. Healthy controls were community workers or students enrolled from PUMCH who were age and gender matched to the patient population. They were free of intestinal, metabolic, cardiovascular or cerebrovascular diseases. Female volunteers were not pregnant. They were with no known allergens. They were neither on any treatment interfering bowel function, nor on any specific diet for weight loss or certain goals. Patients were enrolled from PUMCH who were age and gender matched to the patient population. They were free of intestinal, metabolic, cardiovascular or cerebrovascular diseases. Female volunteers were not pregnant. They were with no known allergens. They were neither on any treatment interfering bowel function, nor on any specific diet for weight loss or certain goals. Patients were selected from our database by a stratified random sampling method. Patients diagnosed with AP based on the Revised Atlanta Classification were included (5). Enrolled patients must be admitted within 24 h after symptom onset. Exclusion
criteria included cancer, chronic pancreatitis, gastroenteritis, inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), necrotizing enterocolitis, and immunocompromised status. Patients on antibiotics, probiotics, Chinese herbs, or laxatives within two months before enrollment were also excluded. All enrolled patients provided informed consent. Our study was approved by the PUMCH Ethics Committee (Identifier: JS1826, Date of approval: 20th February 2018. Period of validity: February 2018 to August 2020). All clinical characteristics were recorded according to standard procedures. Peripheral venous blood from the participants was tested on admission and through disease progression. We collected stool samples with rectal swabs from each participant on admission. Protocols of sample and data collection were described previously (16, 17).

**Demographic and clinical data**

We went through medical records to extract clinical data, such as gender, age, weight, height, comorbidities, lab results, imaging studies, severity stratification, complications, and outcomes. AP was graded into mild AP (MAP), moderately severe AP (MSAP), and severe AP (SAP) (5). NP was defined as pancreatic and/or peripancreatic necrosis (5). Infected NP was either diagnosed based on a positive culture of fine needle aspiration (FNA) of pancreatic and/or peripancreatic necrosis, or the presence of gas in CECT, or the positive culture from the first drainage procedure under sterile conditions. The APACHE II (18), the Balthazar scores (19), and the Sequential Organ Failure Assessment (SOFA) scores (20), were used to evaluate disease severity when NP patients were distinguished from non-NP patients. Local and systematic complications were also defined according to past studies (5, 21). Local complications consisted of acute peripancreatic fluid collection (APFC), acute necrotic collection (ANC), walled-off necrosis (WON), pseudocyst, and infected necrosis. Systematic complications comprised systemic inflammatory response syndrome (SIRS), acute respiratory distress syndrome (ARDS), shock, acute kidney injury (AKI), altered mental status, myocardial injury, liver damage, abdominal compartment syndrome (ACS), and bowel obstruction. Mortality, organ failure, duration of hospital stay, and days of ICU stay were chosen as clinical outcomes.

**DNA collection and extraction, 16S rRNA gene sequencing and processing**

Microbial DNA samples were extracted from rectal swab as previously described using the bead-beating method (22) and then went through gel electrophoresis to determine the quality of the DNA sample. DNA was diluted to 1 ng/L with sterile water and then served as templates to run PCR to amplify the V3-V4 regions (23). High-fidelity enzymes, Phusion® High-Fidelity PCR Master Mix with GC Buffer (New England Biolabs, Ipswich, MA, USA), and primers with Barcode were employed for PCR. After establishing a sequencing library of 16S rRNA V3-V4 regions, an Illumina MiSeq platform (Illumina Inc., San Diego, CA, USA) was used to pool and sequence the purified amplicons.

The bioinformatic analyses of 16s amplicons were accomplished relying on the EasyAmplicon (Version 1.10) (24). Dereplication was achieved by VSEARCH (version 2.15) (25) and the sequences were then denoised into amplicon sequence variants (ASV) with the implemented command in USEARCH (Version 10.0) (26), and an ASV table was generated. The sintax algorithm of USEARCH recognized taxonomic classification of ASVs according to the Ribosomal Database Project (RDP) training set v16 (27).

**Sequencing data analysis and visualization**

The R package vegan (v2.5-6) was applied on Alpha diversity analysis (28). Differences in richness index were evaluated by Turkey’s HSD test. The usearch achieved the weighted UniFrac distance matrix. PCoA (Principal coordinate analysis) was utilized to calculate beta diversity, and Adonis test was applied to verify the difference among groups. The R package ggplot2 visualized the alpha and beta diversity. A Venn diagram illustrating overlapping ASVs among the three groups was created by the R package VennDiagram.

The taxonomic composition was presented either as a stacked bar plot or a chord plot at different taxonomic levels by the ggplot2 package. As for between-group ASV comparisons, the EdgeR method was utilized to calculate the p-value and identify taxonomic features significantly different among groups, and FDR was calculated using the Benjamini-Hochberg method. The volcano plot and Manhattan plot exhibited differential ASVs among groups. Linear discriminant analysis effect size (LEfSe) (http://huttenhower.sph.harvard.edu/galaxy) was utilized for comparison of the intestinal microbiome composition.

**Feature selection by random forest model**

Using 16s sequence profiles and clinical parameters, we randomly divided the samples into a training set and a testing set. We built up a random forest regression model to establish a training set for 70% of the samples and a testing set for the remaining 30% using the R package randomForest. Then, tenfold cross-validation method was applied to the training set.
set. An optimal set of microbial variables was built at the lowest cross-validation error to predict the AP severity, as evaluated by the APACHE II index. We constructed the predictive model with the most important variables, which further went through ROC calculation to distinguish NP patients from non-NP. The pROC R package was used to calculate the confidence intervals for the ROC curves.

**Prediction of gut microbiota phenotype**

The USEARCH-otutab command classified the sequences based on the Greengene database (29). Then, the sequence library was further processed by Bugbase for phenotype prediction of gut flora (30). As for pathway prediction analysis, we used PICRUS2 to predict the possible functional composition based on GO and KEGG database (31). STAMP software (v2.1.3) was used for statistical comparison of the predicted pathways of the microbial community (Welch’s t-test).

**Results**

**Clinical characteristics of enrolled patients**

The study enrolled a total of 58 AP patients and 20 healthy controls. The AP patients were classified into NP and non-NP groups based on a careful evaluation on diagnostic imaging. Table 1 demonstrated the demographic and clinical features of these two groups. The non-NP group had a lower CRP level (median 7.0, IQR 5.0-10.5 vs. median 0.0, IQR 0.0-0.0; p < 0.001), a longer organ failure duration (median 232.1 vs. 74.0, IQR 48.0-276.0 vs. median 0.0, IQR 0.0-0.0; p < 0.001), ARDS (73.7% vs. 17.9%; p < 0.001), AKI (42.1% vs. 10.3%; p = 0.005), shock (36.8% vs. 2.6%; p < 0.001), ACS (26.3% vs. 5.1%; p = 0.021), liver damage (42.1% vs. 5.1%; p = 0.001), myocardial injury (26.3% vs. 0.0%; p = 0.001), and sepsis (47.4% vs. 7.7%; p = 0.001) compared to the non-NP group. Besides, more NP patients were complicated with organ failure (84.2% vs. 20.5%; p < 0.001) and ICU admission (89.5% vs. 7.7%; p < 0.001). And NP patients had a longer organ failure duration (median 74.0, IQR 48.0-276.0 vs. median 0.0, IQR 0.0-0.0; p < 0.001), a longer ICU stay (median 7.0, IQR 5.0-10.5 vs. median 0.0, IQR 0.0-0.0; p < 0.001), and a longer hospital stay (median 23.0, IQR 17.5-30.0 vs. median 6.0, IQR 3.0-11.5; p < 0.001) compared with non-NP patients.

**Microbial profile of patients diagnosed with NP and non-NP**

To determine whether the gut microbial composition may be predictive of NP and AP severity, we collected 58 rectal swabs from AP patients and 20 from healthy controls and performed 16S rRNA sequencing. Sequencing quality was good with no sample discarded and we identified 1664 ASVs in total. As is shown in Figure 1A, the alpha diversity was not significantly different among the three groups, indicating the similarity of global composition between NP and non-NP patients. The species richness rarefaction curves (Figure 1B) flattened out gradually, indicating that the number of individual samples was reasonable. The Venn diagram (Figure 1C) showed the common and unique ASVs detected in NP, non-NP, and HC groups, respectively. As displayed in CPCoA of weighted UniFrac distances (Figure 1D), a significant difference in beta diversity was detected in the microbial compositions among the three groups (p = 0.001).

Taxonomic profiles at different levels of the three groups were presented in Figure 2. *Firmicutes*, *Actinobacteria*, *Bacteroidetes*, and *Proteobacteria* were the predominant phylum in the three groups (Figure 2A). At the order level (Figure 2B), the NP and the non-NP group showed lower relative abundances of *Bifidobacteriaceae* and *Clostridiales* and higher relative abundance of *Lactobacillales* compared with the HC group. In the NP group, *Clostridiales* and *Bacteroidiales* were less abundant, while *Lactobacillales* and *Enterobacteriales* were more abundant, comparing with the non-NP group. As for family level, a chord diagram was constructed to visualize the connections between microbiota composition and the three groups (Figure 2C). Higher abundance of *Enterococcaceae* and lower abundance of *Bacteroidaceae* in the NP group were depicted comparing with the non-NP group. At the genus level, as shown in Figure 2D, NP exhibited a lower relative abundance of *Bifidobacterium* and *Blautia*, which were considered to be probiotic candidates. We also noticed an increased relative abundance of *Enterococcus* and *Escherichia/Shigella* comparing with non-NP. Overall, our finding suggested that AP (both non-NP and NP) might be associated with the decrease of certain taxa of probiotic microbes and the increase of opportunistic pathogens as well.

**Specific taxonomic signatures in NP patients**

A LefSE analysis was performed to reveal the predominant bacterial taxa in NP and non-NP groups (Figure 3A). Manhattan plot (Figure 3B) delineated differential taxa between the NP and the non-NP group at the class level, in which *Bacilli* was enriched, while *Bacteroidia* and *Clostridia* were depleted in the NP group. The volcano plots based on edgeR analysis, as shown in Figures 3C–E, depicted that there were 121, 99, 49 ASVs with...
### TABLE 1  Demographic and clinical characteristics of two groups.

| Variables                      | NP (n = 19) | Non-NP (n = 39) | p-value |
|--------------------------------|-------------|-----------------|---------|
| Age (years), mean (SD)         | 41.8 (11.4) | 47.2 (15.8)     | 0.054   |
| Male, n (%)                    | 12 (63.2)   | 18 (46.2)       | 0.228   |
| BMI (kg/m²), mean (SD)         | 26.1 (4.1)  | 26.2 (3.2)      | 0.723   |
| Overweight (BMI ≥ 25 kg/m²), n (%) | 11 (57.9)  | 19 (48.7)       | 0.515   |
| Obesity (BMI ≥ 30 kg/m²), n (%) | 1 (5.3)     | 4 (10.3)        | 0.528   |
| Smoking, n (%)                 | 7 (36.8)    | 9 (23.1)        | 0.275   |
| Drinking, n (%)                | 6 (31.6)    | 9 (23.1)        | 0.491   |
| Comorbid abnormalities, n (%)  |             |                 |         |
| Hypertension                   | 6 (31.6)    | 13 (33.3)       | 0.895   |
| Diabetes                       | 6 (31.6)    | 7 (17.9)        | 0.247   |
| Fatty liver                    | 14 (73.7)   | 26 (66.7)       | 0.591   |
| Laboratory examinations        |             |                 |         |
| Triglyceride (mmol/L), median (IQR) | 13.6 (12.2, 18.7) | 2.2 (1.2, 18.5) | 0.456   |
| CRP (mg/L), median (IQR)       | 160.0 (131.8, 232.1) | 115.0 (21.5, 160.0) | <0.001  |
| Etiology, n (%)                |             |                 |         |
| Biliary                        | 6 (31.6)    | 19 (48.7)       | 0.220   |
| Hypertriglyceridemia           | 12 (63.2)   | 16 (41.0)       | 0.117   |
| Alcohol consumption            | 1 (5.3)     | 4 (10.3)        | 0.528   |
| APACHE II, median (IQR)        | 9.0 (7.0, 11.0) | 3.0 (2.0, 5.5)  | <0.001  |
| SOFA score, median (IQR)       | 4.0 (2.5, 7.0) | 1.0 (0.0, 1.0)  | <0.001  |
| Balthazar score E, n (%)       | 8 (42.1)    | 0 (0.0)         | <0.001  |
| Disease severity, n (%)        |             |                 |         |
| MAP                            | 0 (0.0)     | 20 (51.3)       | <0.001  |
| MSAP                           | 2 (10.5)    | 18 (46.2)       | 0.008   |
| SAP                            | 17 (89.5)   | 1 (2.6)         | <0.001  |
| Local complications, n (%)     |             |                 |         |
| APFC                           | 19 (100.0)  | 15 (38.5)       | <0.001  |
| Pancreatic pseudocyst          | 1 (5.3)     | 3 (7.7)         | 0.734   |
| ANC                            | 14 (73.7)   | 0 (0.0)         | <0.001  |
| WON                            | 2 (10.5)    | 0 (0.0)         | 0.041   |
| Infected necrosis              | 7 (36.8)    | 0 (0.0)         | <0.001  |
| Systematic complication, n (%) |             |                 |         |
| SIRS                           | 17 (89.5)   | 11 (28.2)       | <0.001  |
| ARDS                           | 14 (73.7)   | 7 (17.9)        | <0.001  |
| AKI                            | 8 (42.1)    | 4 (10.3)        | 0.005   |
| Shock                          | 7 (36.8)    | 1 (2.6)         | <0.001  |
| ACS                            | 5 (26.3)    | 2 (5.1)         | 0.021   |
| Liver damage                   | 8 (42.1)    | 2 (5.1)         | 0.001   |
| Myocardial injury              | 5 (26.3)    | 0 (0.0)         | 0.001   |
| Altered mental status          | 1 (5.3)     | 0 (0.0)         | 0.152   |
| Sepsis                         | 9 (47.4)    | 3 (7.7)         | 0.001   |
| Bowel obstruction              | 6 (31.6)    | 5 (12.8)        | 0.090   |
| Outcome                        |             |                 |         |
| Organ failure, n (%)           | 16 (84.2)   | 8 (20.5)        | <0.001  |
| Organ failure duration (h), median (IQR) | 74.0 (48.0, 276.0) | 74.0 (0.0, 0.0) | <0.001  |
| ICU, n (%)                     | 17 (89.5)   | 3 (7.7)         | <0.001  |

(Continued)
discrepant read counts statistically different between non-NP and HC group, NP and HC group, NP and non-NP group, respectively. 32 ASVs were depleted and 89 ASVs were enriched in non-NP as compared with HC, 33 ASVs were depleted and 69 ASVs were enriched in NP group as compared with HC, 30 ASVs were depleted and 19 ASVs were enriched in NP group as compared with non-NP.

Gut microbiota composition was correlated with clinical indicators

Spearman correlation analysis was performed to recognize the connection between gut microbiota and clinical indicators involving demographic characteristics, laboratory examinations, severity, and outcomes. Enterococcus faecium (ASV2), which

TABLE 1 Continued

| Variables                  | NP (n = 19) | Non-NP (n = 39) | p-value |
|----------------------------|-------------|-----------------|---------|
| ICU stay (days), median (IQR) | 7.0 (5.0, 10.5) | 0.0 (0.0, 0.0) | <0.001 |
| Hospital stay (days), median (IQR) | 23.0 (17.5, 30.0) | 6.0 (3.0, 11.5) | <0.001 |
| Death, n (%)               | 1 (5.3)     | 0 (0.0)         | 0.152   |

NP, necrotizing pancreatitis; SD, standard deviation; BMI, body mass index; CRP, C-reactive protein; IQR, interquartile range; APACHE II, the Acute Physiology and Chronic Health Evaluation II score; SOFA, the Sequential Organ Failure Assessment score; MAP, mild acute pancreatitis; MSAP, moderately severe acute pancreatitis; SAP, severe acute pancreatitis; APFC, acute peripancreatic fluid collection; ANC, acute necrotic accumulation; WON, walled-off necrosis; ARDS, acute respiratory distress syndrome; AKI, acute kidney injury; ACS, abdominal compartment syndrome; SIRS, systemic inflammatory response syndrome; ICU, intensive care unit. CRP was tested at the time of NP diagnosis. APACHE II and SOFA were also calculated at the time of NP diagnosis.
belongs to the family Enterococcaceae, had a higher abundance in NP compared with non-NP (Figure 4A), bearing moderate to strong positive correlation with SOFA, disease severity, ICU stay, hospital stay, and CRP level. Likewise, Clostridium sporogenes (ASV25), found more abundant in the NP group, had a strong and positive correlation to SOFA, organ failure duration, and ICU stay while moderately positively correlated to hospital stay. Klebsiella pneumoniae (ASV94), within the order of Enterobacterales, had a moderate positive correlation with SOFA, organ failure duration, and disease severity.

Altered functional pathways in microbiota of NP patients

We performed a BugBase analysis to predict the bacterial metabolic phenotypes in NP, non-NP, and HC groups, and the anaerobes abundance and mobile elements possession predictions are shown in Figures 5A, B. Compared to HC, non-NP had a significantly lower relative abundance of anaerobes ($p < 0.01$), while NP had a much lower relative anaerobes abundance in contrast to non-NP ($p < 0.05$). In terms of bacteria containing mobile elements, a significantly higher abundance was detected in the non-NP group as compared to the HC group ($p < 0.01$), while there was no significant difference between NP and non-NP ($p = 0.06$). Moreover, we analyzed the metabolic pathways of gut microflora based on PICRUSt2 (Figure 5C). We found that Enterococcus faecium (ASV2), Lactobacillus paracasei (ASV141), Klebsiella pneumoniae (ASV94, ASV108, and ASV144), and Escherichia coli (ASV1), had positive correlation with microbial gene functions concerning staphylococcus aureus infection, phosphotransferase system, ABC transporters, synthesis and degradation of ketone bodies, while they had a negative correlation with antigen processing and presentation, protein digestion and absorption, and restriction enzyme. While for Prevotella timonensis (ASV46), positive correlation to microbial gene functions related to restriction enzyme, protein
digestion and absorption was observed. They had negative correlation with benzoate degradation.

Potential gut microbial features were predictive of NP severity

In order to investigate the value of gut microbial signatures in forecasting NP severity, we applied random forest to identify taxa associated with poor outcomes, as shown in Figure 6. *Finegoldia magna* (ASV3) showed the maximal prediction capacity as a biomarker of NP when performing regression analyses with the APACHE II index. *Enterococcus faecium* (ASV2) had the highest AUC of 0.754 among all single ASVs in the setting of distinguishing NP and non-NP. The combination of two *Clostridium* species (ASV414+ASV262), which had a relatively low abundance in NP groups compared with non-NP, had comparable AUC value with ASV2. We then asked whether the composition of gut bacteria was predictive of infected NP. It turned out that there was not significant difference in AUC between ASV3 as a biomarker and Balthazar CT under the circumstance of infected NP ($p = 0.93$), suggesting the considerable predictive potential of ASV3.

**Discussion**

We explored the intestinal microbiota in patients with NP, non-NP, and healthy controls. Our analysis demonstrated a
significant difference in microbiota composition among the three groups. We then proposed that bacterial biomarkers such as diversity, relative abundance feature, and specific ASVs might be useful to recognize patients who are likely to develop NP.

In our study, CRP, APACHE-II, and SOFA score differ significantly in NP and non-NP, which may be attributed to the severity of NP compared with non-NP. Many researchers have investigated a series of scoring systems from AP severity prediction. Prospective studies compared Ranson score, APACHE II, CTSI, BISAP score, and SOFA score, which were commonly used in clinical settings, in predicting necrosis development (32–34). CTSI had the highest positive predictive value compared with Ranson score,
APACHE II and BISAP (32). However, CTSI is limited by accessibility to contrast enhanced CT (CECT) in the early stage of AP. BISAP score and APACHE II score did not have comparable predicting potential for NP (32). Besides, Ranson score consists of parameters assessed at both admission and after 48h, which is to the disadvantage of early clinical judgement. SOFA score, which was not specifically designed for AP, was more closely related to systemic complications and mortality, rather than local complications such as NP (8, 34). Other researchers generated de novo single factor or...
combination parameters for NP prediction. For instance, CRP (35), red cell distribution width (10) and immature granulocyte percentage (11) were also suggested as predictors of NP. However, these clinical laboratory items are likely to fail considering they are not specific for the complex pathophysiology of NP. A research team recently used machine learning strategy to process data from 2387 AP patients measured in the first 24h of clinical admission (36). They released an on-admission prediction model for NP online which stressed the impacts of gender, total white blood cell count, glucose, alkaline phosphatase, and CRP. However, more clinically relevant data should be included to improve the model. Also, model prediction efficacy usually shifted with various cohort (37).

As for infected NP prediction, studies suggested that sustained increase of procalcitonin (PCT) as a predictor for infected PN if repeatedly measured for a 2-week period (38). Nevertheless, PCT may be false positive in AP patients due to endotoxin translocation from intestine without infection (39). Inflammatory cytokines, such as interleukin 6 (IL6), are also predictor candidates, nevertheless they may be more difficult to access compared with PCT (40). One study reported that the peak of hematocrit (HCT), blood urea nitrogen (BUN), PCT, and CRP within 48h of admission were independent factors for infected PN, and parameters combination added to prediction accuracy. However, the limited sample size and the retrospective design raised issues of potential bias and questionable generalizability. Also, they diagnosed infected PN based on
culture confirmation solely, which may missed false-negative cases.

Intestinal barrier injury, microbial translocation, and local inflammation have been proved to have an essential role in the generation and escalation of AP (13, 41), in which dysbiosis of the gut microbiota is a major contributing factor to intestinal damage (42). A previous study conducted by Zhu et al. showed that AP significantly triggered dysbiosis, and that gut microbiota dysbiosis increased the severity of AP in both animal studies and clinical settings (43). Besides, our previous studies also unveiled varying compositions and functions of gut microbiota in mild and non-mild AP patients, suggesting that altered microbiota might be responsible for the progression of AP (16). Although specific mechanism by which intestinal microflora affects escalation of NP remains unclear, some fundamental progress has been made recently. Zheng et al. reported that certain gut microbiome, for instance, non-pathogenic commensal Escherichia coli, had harmful potential in the human intestine and could aggravate NP through targeting intestinal epithelia (44).

We found that the microbial diversity in NP, species richness in particular, was lower than that in non-NP. Of note, the two groups had different microbiota composition. It is commonly acknowledged that the intestinal microbiota shapes a sophisticated community that bears various physiological and immune-modulating capacities (45). They also play a pivotal role in stimuli for antimicrobial peptides induction (46). Besides, the shift in the balance of symbionts and pathobionts (45), or dysbiosis, has been evidenced to be associated with ulcerative colitis and Crohn’s disease (47). Therefore, we presume that the decreased diversity may result in reduced ecological viability and dysbiosis in the intestine, implicating a weaker defense against pathogenic microorganisms, rendering the gut vulnerable to bacterial translocation that is essential for generating systemic inflammatory response, organ dysfunction, and local complications in AP.

There was consistency of relative abundance throughout different taxonomic levels. Opportunistic pathogens like Enterococcus were more abundant, while probiotic microbes like Bacteroides were less abundant in NP compared with non-NP. Certain Bacteroides species, for instance Bacteroides xylanisolvens, Bacteroides ovatus, and Bacteroides uniformis, played a pivotal role in boosting the gut IgA production, which restored intestinal environment stability by restricting the microorganisms and endotoxin from invading gut epithelial cells, modulating microorganism colonization, and facilitating bacterial clearance (48–50). Enterococci, a common inhabitant of human gastrointestinal tract, usually affect debilitated patients with prolonged hospital admission (51). Our previous study demonstrated that Escherichia/Shigella and Enterococcus were linked to poor prognosis of AP patients, and were commonly culprit pathogens of infected pancreatic necrosis (21). An increased abundance of Enterococcus may lead to higher disease severity (14, 16). Of note, infected NP were recommended to be treated with antibiotics in early disease stage (52). However, certain empiric antibiotics used in hospitalized patients might reduce abundance of the Gram-negative organisms in the GI tract. Depletion of the Gram-negative microbiota weakens the antimicrobial activity towards Gram-positive bacteria including enterococci, leading to overgrowth of enterococci (53, 54).

Besides, in the process of developing antibiotic resistance, certain enterococci lineages, Enterococcus faecium for instance, can colonize the intestine and disseminate to cause systemic infection (51). In this study, Enterococcus faecium was found enriched in NP compared with non-NP. Further, Enterococcus faecium (ASV2) performed best in discriminating NP and non-NP patients based on AUC. A previous study showed that Enterococcus faecium was one of the most frequently identified microbes in patients with infected pancreatic necrosis (55). Simultaneously, we found that Enterococcus faecium was not only correlated with clinical indicators such as CRP, SOFA, disease severity, ICU stay, and hospital stay, but was also connected with many microbial gene functions. Therefore, further studies on the mechanisms by which Enterococcus faecium boosters NP are required. In addition, NP patients had a much lower relative anaerobes abundance than non-NP patients, giving a hint of the selection of antibiotics when dealing with NP.

To be noticed, a combination of clostridium species had similar performance in discriminating NP and non-NP compared with Enterococcus faecium. Previous studies revealed protective effect of certain clostridium species in AP by regulating pancreatic-gut homeostasis. Supplemented Clostridium butyricum strains to mouse model protected against AP (56). At the pancreas level, Clostridium butyricum inhibited dendritic cell and neutrophil infiltration, inflammasome activation, and certain pro-inflammatory pathways. At the gut level, Clostridium butyricum attenuated barrier dysfunction and intestinal inflammation, therefore prevented Enterococcus and Escherichia coli from penetration into pancreas. For inflammatory bowel disease (IBD) patients, significant reduction of Clostridium leptum was observed, which contributed to reduced short chain fatty acids and dysbiosis (57). Analysis of gut microbiota in AP patients with infection complication also revealed decreased bifidobacterial such as Clostridium leptum (58). Probiotic supplementation worth further investigation in AP patients.

Our random Forests regression analysis indicated that Finegoldia magna (ASV3) was the most robust microbial biomarker to predict the prognosis compared to the APACHE II score. Furthermore, we found that in the setting of infected NP, AUCs of Finegoldia magna and Balthazar CT were comparable, implicating that Finegoldia magna could be a potential substitute to assess disease severity of infected NP.
*Finegoldia magna*, a commensal Gram-positive anaerobic coccus (GPAC) that colonizes gastrointestinal tract, is an important opportunistic pathogen. However, due to challenges of high-quality anaerobic specimens collection and difficulties in cultivation, its true impact in clinical settings is possibly underestimated (59). *Finegoldia magna* and its soluble proteins *Finegoldia magna* adhesion factor (FAF) and superantigen protein L activate human neutrophils, promote inflammatory response, and hinder antibacterial peptides or proteins, which may increase virulence (60). Biofilm formation hampers successful antibiotic therapy and results in chronic infections. Relative high resistance of clindamycin (in some studies more than 30.0%) or quinolone (often more than 30%) was observed. And though quite rare, studies also observed resistance of metronidazole, penicillin G, and chloramphenicol (61). 16S rRNA PCR increases the possibility of *Finegoldia magna* detection compared to traditional methods, thus conducive to antibiotic selection and NP outcome prediction. *Finegoldia magna* has virulent factors such as subtilisin-like extracellular serine protease (SufA), superantigen protein L, and *F. magna* adhesion factor (FAF) that prevent clearance by innate defense system. Profound penetration and dissemination of the infections through skin are realized by capsule and tissue-destroying enzymes, as well as SufA. Biofilm contributes to chronic infection (61). However, the relationships between *Finegoldia magna* and the pathophysiology of NP or infected NP remain to be investigated.

In clinical setting, many microorganisms and their constituents have been transformed into robust diagnostic tests for certain diseases. For instance, *Clostridium difficile* and *C. difficile* Toxin A & B (CDAB) are practical diagnostic tests for antibiotic-associated colitis. Therefore, *Enterococcus faecium*, *Finegoldia magna*, and their virulence factors are promising to become cost-effective diagnostic markers.

As for function prediction analysis, we found that species more abundant in NP patients were correlated positively with microbial gene functions related to synthesis and degradation of ketone bodies, and benzoate degradation, while they had a negative correlation with antigen processing and presentation, protein digestion and absorption. While for species less abundant in NP patients, positive correlation to microbial gene functions related to restriction enzyme, protein digestion and absorption was observed, as well as negative correlation with benzoate degradation. A study observed that β-hydroxybutyrate (βOHB), a type of ketone body in circulation, was elevated in patient with non-SAP, but not in SAP (62). Then the researchers used mild or severe form of AP mice to demonstrate that βOHB weakened the pancreatic and systemic proinflammatory macrophages activation by means of class I histone deacetylases. Apart from endogenous ketogenesis, gut microbiota may affect the synthesis and degradation of ketone bodies, which may trigger NP, a non-mild form of AP. Activation of endogenous ketogenesis or supplementation of exogenous βOHB may help with AP prevention and treatment. Intestinal microbial growth may release metabolism excreted by urine. Urine benzoate was elevated in intestinal bacterial overgrowth patients, and was considered a dysbiosis marker (63). Benzoate degradation pathway connected host adrenergic stress to strengthened microorganism virulence, and was implicated in IBD (64). NP and non-NP groups possibly had different benzoate degradation metabolic phenotype, which might imply dysbiosis and bacterial virulence in terms of mechanism. Possible preventive treatment measures regarding metabolic products are worth trying.

Our pilot study had several limitations. Firstly, we took gut microbiome samples at the single time point of admission, but longitudinal monitoring at different time points would enable better understanding of dynamic changes in AP. Secondly, the sample size was limited, thus a multicenter study is needed to verify our results. Thirdly, microbiome taken from various segments of the intestine, whole genome sequencing, and multi-omics will hopefully provide multilevel information to better interpret the mechanisms.

Our study indicated that patients with NP had altered gut microbiome which was predictive for NP patients with worse outcome. *Enterococcus faecium* and *Finegoldia magna*, microbial biomarkers for NP and infected NP, warrant further investigation of their mechanism and clinical application. Our findings may help early prediction of disease progression and inform clinical decision-making in patients with AP.

**Conclusion**

In conclusion, NP patients had distinct features of gut microbiota which can be used to predict disease severity. These features were related to poor clinical prognosis. *Enterococcus faecium* and *Finegoldia magna* were potential microbial biomarkers for prediction of NP and infected NP. Further multi-omics, animal studies, and human trials are required to validate our findings and demonstrate the underlying mechanisms.

**Data availability statement**

The datasets for this article are not publicly available due to concerns regarding participants/patient anonymity. Request to access the datasets should be directed to the corresponding author.

**Ethics statement**

The studies involving human participants were reviewed and approved by PUMCH Ethics Committee (Identifier: JS1826, Date of approval: 20th February 2018. Period of validity:
February 2018 to August 2020. The patients/participants provided their written informed consent to participate in this study.

Author contributions

Conceptualization, MZ, XH, DW. Methodology, XH and DW. Software, XH and YF. Validation, MZ, XH and DW. Formal Analysis, XH, YF. Investigation, MZ, LG, ZH, and LJ. Resources, DW. Data Curation, XH and DW. Writing—Original Draft Preparation, ZY (Zihan Yang) and YF. Writing—Review & Editing, MZ, XH, and DW. Visualization, XH and YF. Supervision, XH, DW. Project Administration, XH, DW. Funding Acquisition, DW. All authors have read and agreed to the published version of the manuscript.

Funding

This study was funded by grants from Chinese National Science Foundation, grant number 32170788, Beijing Natural Science Foundation, grant number 7202152, and National High Level Hospital Clinical Research Funding, grant number 2022-PUMCH-A-026

Conflict of interest

The authors declare that the research was conducted without any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary Material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.988326/full#supplementary-material

References

1. Lankisch PG, Apte M, Banks PA. Acute pancreatitis. Lancet (2015) 386:990–8. doi: 10.1016/S0140-6736(14)60649-8

2. Lee PJ, Papachristou GI. New insights into acute pancreatitis. Nat Rev Gastroenterol Hepatol (2019) 16(8):479–96. doi: 10.1038/s41575-019-0158-2

3. Xiao AY, Tan ML, Wu LM, Asrani VM, Windsor JA, Yadav D, et al. Global incidence and mortality of pancreatic diseases: a systematic review, meta-analysis, and meta-regression of population-based cohort studies. Lancet Gastroenterol Hepatol (2016) 1(1):45–55. doi:10.1016/S2468-1253(16)30004-8

4. Iannuzzi JP, King JA, Leong HJ, Quan J, Windsor JW, Tanyingoh D, et al. Global incidence of acute pancreatitis is increasing over time: A systematic review and meta-analysis. Gastroenterology (2022) 162(1):122–34. doi: 10.1053/j.gastro.2021.09.043

5. Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarra MG, et al. Classification of acute pancreatitis-2012: revision of the Atlanta classification and definitions by international consensus. Gut (2013) 62(1):102–11. doi: 10.1136/gutjnl-2012-302779

6. Maheshwari R, Subramanian RM. Severe acute pancreatitis and necrotizing pancreatitis. Crit Care Clin (2016) 32(2):279–90. doi: 10.1016/j.ccc.2015.12.006

7. Bugiantella W, Rondelli F, Boni M, Stella P, Polistena A, Sanguinetti A, et al. Necrotizing pancreatitis: A review of the interventions. Int J Surg (2016) 28 Suppl 1: S163–71. doi: 10.1016/j.ijsu.2015.12.038

8. Ding N, Guo C, Li C, Zhou Y, Chai X. An artificial neural networks model for early predicting in-hospital mortality in acute pancreatitis in MIMIC-III. BioMed Res Int (2021) 2021:6638919. doi:10.1155/2021/6638919

9. Leonard-Murali S, Lezotte J, Kalka R, Blyden DJ, Patton HJ, Johnson JL, et al. Necrotizing pancreatitis: A review for the acute care surgeon. Am J Surg (2021) 221 (5):827–34. doi: 10.1016/j.amjsurg.2020.08.027

10. Yalçın MS, Tas A, Kara B, Oltner S, Saritas B. New predictor of acute necrotizing pancreatitis: Red cell distribution width. Adv Clin Exp Med (2018) 27 (2):225–8. doi: 10.17219/acem/67590

11. Ünal Y, Barlas AM. Role of increased immature granulocyte percentage in the early prediction of acute necrotizing pancreatitis. Ulus Travma Acil Cerrahi Derg (2019) 25(2):177–82. doi: 10.14744/tjv.2019.70679

12. Harshit Kumar A, Singh Griwan M. A comparison of APACHE II, BISAP, ranson’s score and modified CTSS in predicting the severity of acute pancreatitis. J Clin Gastroenterol (2021) 55. doi: 10.1097/MCG.0000000000001285

13. Capurso G, Zerboni G, Signoretti M, Valente R, Stigliano S, Picicciu M, et al. Role of the gut barrier in acute pancreatitis. J Clin Gastroenterol (2012) 46 Suppl S46–51. doi:10.1097/MCG.0b013e3182652096

14. Tan C, Ling Z, Huang Y, Cao Y, Liu Q, Cui T, et al. Dysbiosis of intestinal microbiota associated with inflammation involved in the progression of acute pancreatitis. Pancreas (2015) 44(6):868–75. doi:10.1097/MPA.0000000000000355

15. Mowbray NG, Beth-Ionnael B, Hammoda M, Shingler G, Al-Sarireh B. The microbiology of infected necrotic pancreas. Hepatobiliary Pancreat Dis Int (2018) 17(5):456–60. doi: 10.1016/j.hpd.2018.08.007

16. Yu S, Xiong Y, Xu J, Liang X, Fu Y, Liu D, et al. Identification of dysfunctional gut microbiota through rectal swab in patients with different severity of acute pancreatitis. Dig Dis Sci (2020) 65(11):3223–37. doi: 10.1007/s10620-020-06061-4

17. Biehl LM, Garzetti D, Farowski I, Ring D, Koepel MB, Rohde H, et al. Usability of rectal swabs for microbiome sampling in a cohort study of hematological and oncological patients. PLoS One (2019) 14(4):e0215428. doi: 10.1371/journal.pone.0215428

18. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med (1985) 13 (10):818–29. doi:10.1097/00003246-198510000-00009

19. Chatziostas C, Roussomoustakaki M, Vardas E, Romanos J, Kouroumalis EA. Balthazar computed tomography severity index is superior to ranson criteria and APACHE II and III scoring systems in predicting acute pancreatitis outcome. J Clin Gastroenterol (2003) 36(3):253–60. doi: 10.1097/00003246-200303000-00013

20. Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. working group on ‘sepsis-related problems’ of the European Society of intensive care medicine. Crit Care Med (1998) 26(11):1793–800. doi:10.1097/00003246-199811000-00016
A. et al. Comparison of BISAP, Ranson necrosis, and mortality in acute pancreatitis. IL-6, CRP, and procalcitonin in predicting severity, organ failure, pancreatic necrosis infection in acute necrotizing pancreatitis.

BugBase predicts organism-level microbiome phenotypes. VSEARCH: a versatile amplicon and metagenomic analysis of microbiome data.

hypercholesterolemic rats. The vegan package. Intestinal microbiota link lymphopenia to murine autoimmunity via

Inflammation and gastrointestinal disorders during acute pancreatitis. Comm Ecol Pack (2017) 4:e2584. doi:10.7717/peerj.2584

Castoldi A, Favero de Aguiar C, Moraes-Vieira PM, Olsen Saraiva Camara M-JC, Vicaut E, Panis YH, Lajeunie EJ, et al. Gut microbiome composition and function in experimental colitis during inflammatory bowel disease. Nat Biotechnol (2018) 36(3):467–51. doi:10.1038/nbt.4161

Kabeerdoss J, Sankaran V, Pugazhendhi S, Ramakrishna BS. Clostridium perfringens and Pseudomonas aeruginosa aggravate acute necrotizing pancreatitis through targeting of intestinal epithelial cells. Appl Environ Microbiol (2019) 85(12):e00599–19. doi:10.1128/AEM.00599–19

42. Castoldi A, Favero de Aguiar C, Moraes-Vieira PM, Olsen Saraiva Camara M-N. The rise of the enterococcus: beyond vancomycin resistance. Nat Rev Microbiol (2012) 10(4):266–78. doi:10.1038/nrmicro2761

43. Alfonso V, Gomez JL, Gutiérrez A, Moreno-Osset E, del Valle R, Anton M, et al. Iga production in the large intestine is modulated by a different mechanism than in the small intestine: Bacteroides acidifaciens promotes Iga production in the large intestine by inducing germinal center formation and increasing the number of IgA+ B cells. Immunology (2013) 138(4):645–51. doi:10.1111/j.1365-2567.2012.03715.x

44. Zheng J, Lou L, Fan J, Huang C, Mei Q, Wu J, et al. Commensal escherichia coli aggravates acute necrotizing pancreatitis through targeting of intestinal epithelial cells. Appl Environ Microbiol (2019) 85(12):e00599-19. 10.1128/AEM.00599-19

45. Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol (2009) 9(5):313–23. doi:10.1038/nri2515

46. Mukherjee S, Vaishnava S, Hooper LV. Multi-layered regulation of intestinal antimicrobial defense. Cell Mol Life Sci (2008) 65(19):3019–27. doi:10.1007/s00018-008-8182-3

47. Frank DN, St Amand AL, Feldman RA, Boedeker EC, Harpaz P, Pace NR. Molecular phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases. Proc Natl Acad Sci U.S.A. (2007) 104(34):13780–5. doi:10.1073/pnas.0706251104

48. Yang C, Mogno I, Conticchio EJ, Bjergerdung IN, Aggawala V, Li Z, et al. Fecal Iga levels are determined by strain-level differences in bacterial ovatus and are modifiable by gut microbiota manipulation. Cell Host Microbe (2020) 27(3):467–75. doi:10.1016/j.chom.2020.01.016

49. Nagababu T, Hosono A, Oyama A, Tsuda M, Suzuki A, Hachimura S, et al. Iga production in the large intestine is modulated by a different mechanism than in the small intestine: Bacteroides acidifaciens promotes Iga production in the large intestine by inducing germinal center formation and increasing the number of IgA+ B cells. Immunology (2013) 138(4):645–51. doi:10.1111/j.1365-2567.2012.03715.x

50. Lopez-Almeida I, Romani-Perez M, Bullich-Vallrubias C, Benitez-Paer A, Gomez Del Pulgar EM, Frances R, et al. Bacteroides uniformis combined with fiber amplifies metabolic and immune benefits in obese mice. Gut Microbes (2021) 13(11):1–20. doi:10.1080/19490976.2021.1953842

51. Arias CA, Murray BE. The rise of the enterococcus: beyond vancomycin resistance. Nat Rev Microbiol (2012) 10(4):266–78. doi:10.1038/nrmicro2761

52. Arvanitakis M, Dumonceau JM, Albert J, Badoua A, Bali MA, Barthet M, et al. Endoscopic management of acute necrotizing pancreatitis: European society of gastrointestinal endoscopy (ESGE) evidence-based multidisciplinary guidelines. Endoscopy (2018) 50(5):524–46. doi:10.1055/a-0588-5365

53. Brandt K, Pita G, Mihu CN, Uceda C, Jia T, Flesher M, et al. Vancomycin-resistant enterococci exploit antibiotic-induced innate immune deficits. Nature (2008) 455(7214):804–7. doi:10.1038/nature07259

54. Kinnebrew MA, Uceda C, Zendewicz LA, Smith N, Flavell RA, Pamer EG. Bacterial flagellin stimulates toll-like receptor 5-dependent defense against vancomycin-resistant enterococcal infection. J Infect Dis (2010) 201(4):534–43. doi:10.1086/650203

55. Sahar N, Konarek A, Kanji ZS, Chuhara S, Gain SL, Irani S, et al. The microbiology of infected pancreatic necrosis in the era of minimally invasive therapy. Eur J Clin Microbiol Infect Dis (2018) 37(7):1353–9. doi:10.1007/s10096-018-3259-x

56. Pan LL, Niu W, Fang X, Liang W, Li H, Chen W, et al. Clostridium butyricum strains suppress experimental acute pancreatitis by maintaining intestinal homeostasis. Mol Nutr Food Res (2019) 63(10):1801497. doi:10.1002/mnfr.201901497

57. Kaberedos J, Sankaran V, Pugazhendhi S, Ramakrishna BS. Clostridium leptum group bacteria abundance and diversity in the fecal microbiota of patients with inflammatory bowel disease: a case-control study in India. BMC Gastroenterol (2013) 13:20. doi:10.1186/1471-230X-13-20

58. Gen M-E, Wang F, Su Y, Zhang W-J, Sun B, Wang G. Gastrointestinal microbiome: a crucial and potential target in acute pancreatitis. Apoptosis (2018) 23(7):377–87. doi:10.1007/s10495-018-1464-9

59. Murphy EC, Frick IM. Gram-positive anaerobic cocci-commensals and opportunistic pathogens. FEMS Microbiol Rev (2013) 37(4):520–53. doi:10.1111/femsr.12005

60. Neumann A, Björck L, Frick I-M. Flagelloida magna, an anaerobic gram-positive bacterium of the normal human microbiota, induces inflammation by activating neutrophils. Front Microbiol (2020) 11. doi:10.3389/fmicb.2020.00065

61. Boyanova L, Markovska R, Mitov I. Virulence arsenal of the most opportunistic pathogens. FEMS Microbiol Rev (2013) 37(4):520–53. doi:10.1111/femsr.12005

62. Zhang L, Shi J, Du D, Niu N, Liu S, Yang X, et al. Ketogenesis acts as an important determinant of severity for acute pancreatitis in a tertiary teaching hospital. J Gastroenterol (2019) 54(3):347–58. doi:10.1007/s00535-018-1529-0

63. Lord RS, Bralley JA. Clinical applications of urinary organic acids. Perspect Biol Med (2009) 52:161–70. doi:10.1353/pbm.0.0047

64. Rooks MG, Veiga P, Wardwell-Scott LH, Tickle T, Segata N, Michaud M, et al. Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission. Isme J (2014) 8(7):1403–17. doi:10.1038/ismej.2014.3